Ionizing radiation induces tumor cell lysyl oxidase secretion by Shen, C J et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Ionizing radiation induces tumor cell lysyl oxidase secretion
Shen, C J; Sharma, A; Vuonag, D-V; Erler, J T; Pruschy, M
Abstract: BACKGROUND: Ionizing radiation (IR) is a mainstay of cancer therapy, but irradiation
can at times also lead to stress responses, which counteract IR-induced cytotoxicity. IR also triggers
cellular secretion of vascular endothelial growth factor, transforming growth factor ￿ and matrix metallo-
proteinases, among others, to promote tumor progression. Lysyl oxidase is known to play an important
role in hypoxia-dependent cancer cell dissemination and metastasis. Here, we investigated the effects of
IR on the expression and secretion of lysyl oxidase (LOX) from tumor cells. METHODS: LOX-secretion
along with enzymatic activity was investigated in multiple tumor cell lines in response to irradiation.
Transwell migration assays were performed to evaluate invasive capacity of naïve tumor cells in response
to IR-induced LOX. In vivo studies for confirming IR-enhanced LOX were performed employing im-
munohistochemistry of tumor tissues and ex vivo analysis of murine blood serum derived from locally
irradiated A549-derived tumor xenografts. RESULTS: LOX was secreted in a dose dependent way from
several tumor cell lines in response to irradiation. IR did not increase LOX-transcription but induced
LOX-secretion. LOX-secretion could not be prevented by the microtubule stabilizing agent patupilone. In
contrast, hypoxia induced LOX-transcription, and interestingly, hypoxia-dependent LOX-secretion could
be counteracted by patupilone. Conditioned media from irradiated tumor cells promoted invasiveness of
naïve tumor cells, while conditioned media from irradiated, LOX- siRNA-silenced cells did not stimulate
their invasive capacity. Locally applied irradiation to tumor xenografts also increased LOX-secretion in
vivo and resulted in enhanced LOX-levels in the murine blood serum. CONCLUSIONS: These results
indicate a differential regulation of LOX-expression and secretion in response to IR and hypoxia, and
suggest that LOX may contribute towards an IR-induced migratory phenotype in sublethally-irradiated
tumor cells and tumor progression.
DOI: 10.1186/1471-2407-14-532
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-99935
Published Version
 
 
Originally published at:
Shen, C J; Sharma, A; Vuonag, D-V; Erler, J T; Pruschy, M (2014). Ionizing radiation induces tumor
cell lysyl oxidase secretion. BMC Cancer, 14:532. DOI: 10.1186/1471-2407-14-532
RESEARCH ARTICLE Open Access
Ionizing radiation induces tumor cell lysyl oxidase
secretion
Colette J Shen1,2†, Ashish Sharma1†, Dinh-Van Vuong1, Janine T Erler3, Martin Pruschy1*†
and Angela Broggini-Tenzer1†
Abstract
Background: Ionizing radiation (IR) is a mainstay of cancer therapy, but irradiation can at times also lead to stress
responses, which counteract IR-induced cytotoxicity. IR also triggers cellular secretion of vascular endothelial growth
factor, transforming growth factor β and matrix metalloproteinases, among others, to promote tumor progression.
Lysyl oxidase is known to play an important role in hypoxia-dependent cancer cell dissemination and metastasis.
Here, we investigated the effects of IR on the expression and secretion of lysyl oxidase (LOX) from tumor cells.
Methods: LOX-secretion along with enzymatic activity was investigated in multiple tumor cell lines in response to
irradiation. Transwell migration assays were performed to evaluate invasive capacity of naïve tumor cells in response
to IR-induced LOX. In vivo studies for confirming IR-enhanced LOX were performed employing immunohistochemistry
of tumor tissues and ex vivo analysis of murine blood serum derived from locally irradiated A549-derived tumor
xenografts.
Results: LOX was secreted in a dose dependent way from several tumor cell lines in response to irradiation.
IR did not increase LOX-transcription but induced LOX-secretion. LOX-secretion could not be prevented by the
microtubule stabilizing agent patupilone. In contrast, hypoxia induced LOX-transcription, and interestingly,
hypoxia-dependent LOX-secretion could be counteracted by patupilone. Conditioned media from irradiated tumor
cells promoted invasiveness of naïve tumor cells, while conditioned media from irradiated, LOX- siRNA-silenced
cells did not stimulate their invasive capacity. Locally applied irradiation to tumor xenografts also increased
LOX-secretion in vivo and resulted in enhanced LOX-levels in the murine blood serum.
Conclusions: These results indicate a differential regulation of LOX-expression and secretion in response to IR and
hypoxia, and suggest that LOX may contribute towards an IR-induced migratory phenotype in sublethally-irradiated
tumor cells and tumor progression.
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Background
Ionizing radiation (IR) is a mainstay of cancer therapy,
but resistance to therapy often leads to recurrence and
poor outcome for cancer patients. Several studies have
uncovered sources of intrinsic resistance to radiation,
such as hypoxia, activation of oncogenes and cell signaling
pathways and defects in apoptosis and DNA damage re-
pair [1-6]. However, mechanisms of acquired resistance to
IR are poorly understood. Several studies have suggested
that radiation can lead to stress responses that allow con-
tinued tumor survival and progression, thus hindering its
therapeutic benefit. For instance, IR stimulates the activa-
tion of the hypoxia-inducible transcription factor (HIF)-1
and subsequent expression and secretion of the tumor
vascular endothelial growth factor (VEGF) to protect the
tumor vasculature [7,8]. IR also induces expression of the
transforming growth factor β (TGF-β) and thereby TGF-
β-mediated epithelial-to-mesenchymal transition in mam-
mary epithelial cells [9], and activation of the epidermal
growth factor receptor (EGFR) thereby promoting tumor
growth [10]. Further, IR-induced matrix metalloproteinase
activity enhances the invasive capacity of multiple cancer
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cell types, including melanoma, prostate cancer, pancre-
atic cancer, hepatocellular carcinoma and glioma [11-17]
and initiates myeloid cell recruitment relevant for vasculo-
genesis [18,19]. IR also upregulates integrin expression
promoting a cellular invasive phenotype [17,20].
Lysyl oxidase (LOX) is a cell-secreted amine oxidase that
crosslinks collagen and elastin in the extracellular space,
resulting in increased tissue stiffness and tensile strength.
It is secreted as an inactive 50 kDa proenzyme and cleaved
extracellularly to a 32 kDa active enzyme [21,22]. To date,
LOX has been shown to be induced by hypoxia and sev-
eral cytokines, including TGF-β [23-25]. While its role in
the morphogenesis and repair of connective tissues is well
established, recent work has suggested an important role
in cancer progression [26]. High tumor LOX expression is
associated with poor distant metastasis-free and overall
survival in patients. Furthermore, LOX promotes tumor
growth and progression in vivo, cancer cell invasion, and
premetastatic niche formation to foster distant metastases
[22,27-30]. As part of an autocrine loop LOX also drives
VEGF-expression and subsequent tumor angiogenesis
through LOX-activated PDGF-receptor signaling [31]. In
this study, we investigate the effects of IR on LOX secre-
tion by tumor cells to determine a putative role in an IR-
induced stress response, which might promote treatment
resistance. We demonstrate that clinically relevant doses
of IR enhance LOX secretion in vitro and in vivo and that
IR-induced LOX stimulates tumor cell invasion on a func-
tional level. Furthermore, our expression and combined
treatment studies with microtubule-stabilizing agents sug-
gest that LOX expression and secretion are differentially
regulated by hypoxia and ionizing radiation.
Methods
Cell culture, reagents, and irradiation
All cell culture media and supplements were obtained
from Gibco (Invitrogen). The human lung adenocarcin-
oma cells A549 were grown in RPMI 1640 medium, and
the human colon adenocarcinoma cells SW620 were
grown in DMEM. All media were supplemented with 10%
(v/v) fetal bovine serum, 1% (v/v) penicillin-streptomycin,
and 1% (v/v) L-glutamine, and cells were cultured at 37°C
in a 5% CO2 humidified incubator. Additional cell lines
used for the exhaustive screening included H125 (lung
cancer); HCT116, HT29, SW480 (colon cancer); LN18,
U251 (glioma); D341, DAOY (medulloblastoma); A431
(vulval cancer) and MDA-MB-231 (breast cancer).
These cell lines were also grown in the fully supple-
mented RPMI1640-medium.
Patupilone (Epothilone B, EPO906) was provided by
Novartis Pharma AG (Basel, Switzerland). To prepare
conditioned cell culture medium (CM), cells were initially
seeded in serum-containing medium for 24-48 hours and
then sham-treated or irradiated with the indicated doses
of IR. The cell culture medium was discarded 1 hour later,
and cells were rinsed once in PBS and incubated for an
additional 16-20 hours in exactly 10 ml of serum-free cul-
ture medium. Conditioned cell culture medium was col-
lected and immediately filtered through a 0.45 μm sterile
filter to remove any floating cells, then concentrated in
10,000 NMWL Centricon filter devices (Millipore) by cen-
trifuging at 4000 × g for 15 minutes at 4°C to exactly
400 μl of concentrated CM. The total amount of protein
in concentrated CM was determined using a NanoDrop
Spectrophotometer. Concentrated CM was stored at -80°C.
For patupilone treatment, cells were pretreated with DMSO
(control) or 0.5 nM patupilone 24 hours prior to irradiation.
Irradiation was performed at room temperature using a
Primart 6 MV X-ray linear accelerator unit (Siemens) at
2.8 Gy/min or an Xstrahl 200 kV X-ray unit at 1 Gy/min.
siRNA transfection
Transfection was performed using backward transfection
with Lipofectamine RNAiMAX (Invitrogen). siRNAs for
downregulation of human LOX (NM_002317.5) and fire-
fly luciferase (control) were synthesized by Microsynth
(Switzerland) and used at 20 nM concentration. siRNA se-
quences are as follows (5’-3’): siLOX, CAAUGCUCCUA
CUGUUUAAdTdT; siLuc, CGUACGCGGAAUACUUCG
AdTdT.
Quantitative real-time RT-PCR
Sample RNA was isolated using an RNeasy Mini Kit
(Qiagen), then quantified using a NanoDrop spectro-
photometer. RNA was reverse-transcribed using a High
Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems), and the resulting cDNA was amplified using
FastStart Universal SYBR Green Master Mix (Roche) on
an Applied Biosystems 7900HT real-time PCR instru-
ment. Gene expression values represent 2-ΔΔCt, normal-
ized to 18S rRNA. The following primers were used (5’-
3’): LOX forward, CGTCCACGTACGTGCAGAAG; LOX
reverse, CCTGTATGCTGTACTGGCCAGAC; CDKN1A
forward, GGACCTGGAGACTCTCA; CDKN1A reverse,
CCTCTTGGAGAAGATCAG; 18S forward, ATGGCCGT
TCTTAGTTGGTG; 18S reverse, CGCTGAGCCAGT
CAGTGTAG.
Immunoblotting, antibody array and ELISA
LOX secretion was determined by Western blotting per-
formed on concentrated CM samples using an antibody
against LOX (NB100-2527, Novus Biologicals). Angio-
genesis array on conditioned media was performed using
the Human Angiogenesis array (R&D systems) according
to the manufacturer`s protocol. For ELISA, cells derived
from different tumor entities were sham-treated or ir-
radiated and conditioned media was harvested 24 h
after treatment. LOX protein levels were measured
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according to the protocol of the commercially available
LOX-ELISA-kit (USCN Life Science Inc.). Simultaneous
quantification of the number of viable cells was performed
to allow correction of LOX -levels for cell number.
LOX and LDH activity assay
To assess LOX enzymatic activity in CM, a fluorometric
assay detecting the level of hydrogen peroxide was per-
formed as previously described [32] using a freshly pre-
pared enzyme mixture containing 1.2 M urea (Sigma-
Aldrich), 50 mM sodium borate pH 8.0 (Sigma-Aldrich),
0.01 M calcium chloride (Sigma-Aldrich), and 1.0 U/mL
horseradish peroxidase (Sigma-Aldrich), followed by 50 μL
of freshly prepared substrate mixture containing 1.2 M
urea (Sigma-Aldrich), 50 mM sodium borate pH 8.0
(Sigma-Aldrich), 0.01 M calcium chloride (Sigma-
Aldrich), 0.01 M diaminopentane (Sigma-Fluka), and
10 μM amplex red (Invitrogen). To determine lactate
dehydrogenase (LDH)-release conditioned media was
harvested from sham-treated and irradiated A549 cells,
24 hours after irradiation, LDH-activity was determined
using the CytoTox 96 Non-Radioactive Cytotoxicity
Assay (Promega). Purified LDH was used as a positive
control.
Transwell invasion assay
To assess cellular invasion in response to experimental
manipulations, naïve A549 cells (15,000 cells/insert)
were seeded in serum-free medium on Transwell inserts
(6.5 mm, 8 μm pores, Costar) coated with 50 μg/ml rat
tail collagen I (Becton Dickinson). CM from A549 cells
first transfected with control or LOX siRNA and then
treated with 0 or 5 Gy IR was used to attract migrating
cells. For CM preparation, after irradiation, the same num-
ber of cells from each condition was seeded in serum-
containing medium, and CM was collected after 24 hours.
Cells seeded in inserts were allowed to migrate for 24 hours.
For quantification, cells from the upper side of the insert
were scraped away with cotton swabs, and then inserts
were fixed in 75% methanol/25% acetic acid (v/v) and
stained with DAPI. Invaded cells were counted manually
under a fluorescent microscope.
Tumor xenograft experiments and immunohistochemistry
A549 tumor xenograft experiments were carried out as
previously described [33]. At a tumor volume of 200-
250 mm3, tumors were sham-irradiated or irradiated
using a customized shielding device with 1 or 2 × 10 Gy,
respectively, using an Xstrahl 200 kV X-ray unit at
1 Gy/min. IR-treated animals were sacrificed 24 h after
the last fraction of IR-treatment or 48 hours after the
last fraction of high dose IR-treatment. Blood serum
was derived from heart-punctured animals following eu-
thanasia. For immunohistochemistry tumor xenografts
were fixed in 4% PBS-buffered formalin and embedded
in paraffin. Sections (3 mm) were mounted on glass slides,
deparaffinized, rehydrated and stained with H&E or a
LOX-specific antibody (Novus Biologicals, NB100-2527).
Whole tumor sections were quantified for specific LOX-
staining intensities. Each treatment group consisted of 3
animals and at least 3 sections per tumor were analyzed.
All in vivo experiments were performed in strict ac-
cordance with the guidelines for the welfare and use of
animals of the Swiss Cantonal Veterinary Authorities
and approved by the same Authorities (Permit Number:
145/2011).
Statistical analysis
Statistical analysis was performed using Student`s t-test
and one- or two-way ANOVA analysis. All experiments
were conducted as at least 3 independent times. Results
are plotted as mean ± SEM; the level of significance was
set at P < 0.05 (*) and P < 0.005 (**).
Results
Ionizing radiation promotes LOX-secretion by tumor cells
To explore the cellular stress response to ionizing radi-
ation (IR) with regard to LOX, human A459 lung adeno-
carcinoma cells were irradiated with increasing doses of
IR. 16-20 hours after irradiation, the amount and the en-
zymatic activity of LOX secreted into conditioned medium
(CM) were determined by western blotting, ELISA and
a fluorometric activity assay, respectively. Interestingly,
we noted increased secretion of both active LOX en-
zyme and inactive LOX pro-enzyme by human A549
lung adenocarcinoma cells in response to increasing
doses of IR, with cells treated with 10 Gy of IR secreting
approximately 15 times more active LOX enzyme than
control cells (Figure 1A). The total amount of proteins
in CM was only minimally changed and equal amounts
of protein were loaded for SDS-PAGE and immunoblot-
ting. The increase in LOX secretion was paralleled by an
increase in LOX activity as determined in CM, derived
from cells treated with increasing doses of IR (Figure 1B).
To exclude an unspecific leakage of proteins in CM due
to IR-damaged cells, CM were also tested against several
other secreted proteins. A secretion profile of multiple
factors was obtained using antibody arrays. Known
secretory factors such as PDGFA (platelet derived growth
factor alpha) showed increased secretion in response to IR
whereas THBS1 (Thrombospondin 1) levels decreased
with IR in a dose dependent manner. Furthermore,
LDH, a classic marker for cell leakage, was not increased
in response to irradiation (Additional file 1: Figure S1).
Thus, no general protein leakage could be observed, indi-
cating specific, IR-mediated LOX secretion.
To confirm IR-enhanced LOX secretion in additional
cell lines, a LOX-directed ELISA was used to quantitatively
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Figure 1 LOX secretion and activity in response to tumor cell irradiation. (A) Western blot of LOX zymogen (50 kD) and active form (32 kD)
in conditioned media derived from irradiated A549 lung carcinoma cells 16-20 h after irradiation and quantification of band intensities from 3
independent experiments. (B) LOX activity in conditioned media derived from irradiated A549 lung carcinoma cells 16-20 h after irradiation,
averaged over 3 independent experiments (*: significantly different vs control samples, p < 0.05).
Figure 2 LOX secretion in response to tumor cell irradiation from different tumor cell lines. ELISA-based quantification of LOX in supernatants
from irradiated tumor cell lines (*: significantly different for 5 and 10 Gy vs control samples, p < 0.05; **: significantly different only for 5 Gy vs control
samples, p < 0.05).
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detect the level of LOX in supernatants of irradiated tumor
cells (0, 5, 10 Gy). With the exception of MDA-MB-231
cells, all tumor cell lines studied demonstrated enhanced
LOX secretion in response to IR, but to different magni-
tudes depending on the cell type (Figure 2). To probe the
level of secreted LOX over time, LOX was analyzed in
CM of selected, irradiated cell lines at several time
points after irradiation (10 Gy). A steady increase of se-
creted LOX, even though to different extents, could be
determined in all three cell lines investigated (A549,
SW620, A431) (Additional file 2: Figure S2). These results
suggest that several tumor cell types exhibit increased
LOX secretion in response to IR as a mode of stress
response but that each tumor cell type may respond diffe-
rently to varying doses of IR.
Patupilone inhibits hypoxia-induced but not IR-induced
LOX secretion
The microtubule stabilizing agent patupilone has pre-
viously been shown to abrogate hypoxia-induced protein
expression, to sensitize for radiotherapy and to inhibit
IR-induced VEGF and MMP secretion [11,34-38]. Thus,
patupilone could potentially be used in combination
with IR to abrogate any IR-induced LOX-related invasive
or malignant phenotype. To investigate a putative counter-
acting effect of patupilone on IR-induced LOX-secretion,
Figure 3 Patupilone counteracts hypoxia- but not IR-induced LOX-secretion. (A) Western blot of basal and IR-induced LOX in conditioned
media derived from patupilone-untreated or patupilone-pretreated (0.5 nM) cells and quantification of band intensities from 3 independent
experiments. (B) Western blot of basal and hypoxia-induced LOX in conditioned media derived from patupilone-untreated or patupilone-pretreated
(0.5 nM) cells and quantification of band intensities from 3 independent experiments. (C) LOX gene transcription 16 h after irradiation and hypoxia,
determined by RT-PCR, averaged over 3 independent experiments.
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A459 tumor cells were pretreated with patupilone 24 hours
prior to irradiation and LOX-secretion in CM was mea-
sured over 16-20 hours after irradiation. No change in
basal or IR-induced LOX secretion was observed in CM
derived from un-treated or pretreated cells with 0.5 nM
patupilone, a dose previously shown to inhibit IR-induced
VEGF and MMP-secretion in A549 cells (Figure 3A)
[11,38]. These results suggest potentially different mecha-
nisms governing LOX and VEGF or MMP secretion in re-
sponse to IR.
Even though patupilone did not affect IR-induced
LOX secretion, we investigated hypoxia-induced LOX
secretion to be regulated by patupilone. To this end, A549
tumor cells were pretreated with patupilone (0.5 nM) for
24 hours, followed by cell culture in normoxic and hypo-
xic (0.2% oxygen) conditions for 16-20 hours. Thereafter,
conditioned media were collected to assess LOX secretion.
As opposed to IR-induced LOX-secretion, hypoxia-
induced LOX secretion was abrogated in patupilone-
pretreated cells to the basal level as observed under
normoxic conditions (Figure 3B). These results suggest
that patupilone could potentially be used to inhibit LOX
secretion from hypoxic tumors but that, at least at the
concentration used here, patupilone might not prevent
IR-induced LOX secretion. Furthermore, these results
suggest differential mechanisms governing LOX secre-
tion promoted by hypoxia and IR.
In contrast to previously investigated HIF-1-mediated
LOX-secretion in response to hypoxia, IR-induced LOX
secretion did not result from increased LOX-transcription
in the A549 lung adenocarcinoma cells. While hypoxia
strongly induced LOX gene expression, LOX-transcription
remained constant in response to irradiation with increas-
ing doses of IR as determined at the 16 h time point after
irradiation (Figure 3C; see Additional file 3: Figure S3 for
the SW620 colon carcinoma cell line). IR-induced
LOX-transcription could not be observed at earlier or
later time points after irradiation either (A549, SW620;
Additional file 4: Figure S4). Thus, enhanced LOX secre-
tion in response to irradiation does not result from in-
creased transcription but rather from a post-transcriptional
mechanism.
IR-induced LOX promotes the invasive capacity of naïve
tumor cells.
LOX promotes cancer cell invasion and dissemination.
To determine a functional role of IR-induced LOX se-
cretion, we analyzed the invasive capacity of naïve A549
cells, stimulated with conditioned media derived from
sham- or irradiated control and anti-LOX siRNA-targeted
A549 tumor cells (Figure 4A). We observed a 50% in-
crease in the number of invaded cells in the cell popula-
tion stimulated with conditioned medium derived from
irradiated, control-transfected cells when compared to
Figure 4 IR-induced LOX promotes the invasive capacity of naïve tumor cells. (A) Western blot of LOX in conditioned media derived from
untreated and irradiated A549 cells, transfected with siLuc-control or siLOX-RNA. (B) Representative pictures of invaded A549 tumor cells stimulated
with conditioned medium derived from un-irradiated and irradiated, siLuc-control- and siLOX-RNA transfected cells. (C) Quantification of invading
A549 tumor cells stimulated with conditioned medium derived from un-irradiated and irradiated, siLuc-control- and siLOX-RNA transfected cells,
averaged over 3 independent experiments.
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sham-irradiated cells (Figure 4B-C). Interestingly, con-
ditioned media derived from irradiated, LOX siRNA-
transfected cells did not stimulate the invasive capacity
of naïve A549 tumor cells, thereby demonstrating LOX-
specificity. These results suggest that IR-induced LOX
might promote an invasive tumor cell phenotype in
naïve or sublethally irradiated cells.
Irradiated tumor xenografts exhibit increased LOX
secretion
Our studies demonstrated an increase of LOX secretion in
irradiated tumor cell lines in vitro. To confirm these fin-
dings in vivo, we analyzed LOX secretion in A549-derived
tumor xenografts in mice. Tumors were sham-irradiated,
irradiated with a single dose of 10 Gy or irradiated with
2× 10 Gy, with the second dose applied 12 hours after the
initial dose of IR. Tumors were then harvested for immu-
nohistochemical analysis 24 and 48 hours after the single
and last fraction of irradiation, respectively. We detected
increased LOX-staining in tumor sections irradiated with
both regimens of IR, with more enhanced LOX-staining at
the 48 hour time point after irradiation (Figure 5A, see
Additional file 5: Figure S5). Next, we also determined the
level of human,tumor-derived LOX in the serum of tumor
xenografted mice, which were irradiated with the two
treatment regimens. We could not detect a change in the
basal level of LOX 24 hours after irradiation. Interestingly
though, an increased amount of LOX could specifically be
detected in the serum of mice 48 hours after irradiation
with 10 Gy. This level was even further increased in
the serum of mice that were irradiated with the additional
IR-fraction of 10 Gy (Figure 5B). Locoregional irradiation
of mice not carrying tumor xenografts did not result in in-
creased LOX in the serum above basal level and mouse-
LOX levels did not change (data not shown). Thus, our
results confirm that IR can also promote LOX secretion
from tumors in vivo.
Discussion
In this study, we demonstrated that LOX tumor cell
secretion is promoted by IR in vitro and in vivo and that
IR-induced LOX functionally promotes invasion of can-
cer cells in vitro. These findings suggest that LOX con-
tributes to a coordinated stress response of cancer cells
to IR. Along with increased secretion of VEGF, MMP,
and TGF-β, among others [12-17], these responses may
lead to cell survival, invasion, and dissemination of sub-
lethally irradiated cancer cells and thereby contribute to
locoregional and distant treatment failure.
LOX gene expression is induced by the activation of the
primary transcription factor HIF-1α under hypoxia [23],
but also in response to several cytokine-activated signal
transduction cascades [23-25,39]. Eventually, this results
in enhanced LOX levels secreted into the microenviron-
ment. We here demonstrate that irradiation of tumor cells
will also lead to increased amounts of secreted LOX, how-
ever in a gene transcription- and hypoxia-independent
way. While hypoxia activates the transcriptional activity of
HIF-1α and subsequently LOX-gene expression, IR did
not activate HIF-1α or LOX-gene expression, at least in
the cell systems investigated in this report (HIF-1α, data
not shown). Elevated LOX levels could be identified in re-
sponse to irradiation in conditioned media derived from
established tumor cells from multiple different tumor en-
tities and to different magnitudes. But so far we have not
identified a correlation between IR-induced LOX levels
and radiosensitivity in the cell lines investigated.
Thus, irradiation and hypoxia most probably regulate
LOX via differential pathways, but the mechanism of IR-
induced LOX-secretion remains elusive. TGF-β1 regulates
Figure 5 IR-enhanced LOX in tumor xenografts. (A) Tumor tissue from A549-derived tumor xenografts treated with 1 × 10 Gy and 2 × 10 Gy
(with 12 h between fractions) and evaluated by immunohistochemistry for LOX at different time points after irradiation. Whole tumor sections
were quantified for specific LOX-staining intensity. Each treatment group consists of 3 animals. At least 3 sections per tumor/animal were analyzed.
(B) LOX in murine blood serum derived from mice with untreated or locally irradiated A549 tumor xenografts and quantified by ELISA at different time
points after irradiation. Each treatment group consists of 3 animals.
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LOX activity in osteoblastic cells on the pre-and post-
translational level [40], so IR-induced TGF-β1 could play
a role in promoting LOX secretion from our tumor cells.
Other possible mechanisms could involve IR-stimulated
PI3K/Akt/mTOR signaling, a known stress response path-
way to promote LOX protein synthesis. However, we
could not detect IR-enhanced LOX-transcription. We
exclude that LOX unspecifically leaked out from IR-
damaged cell membranes since the total protein amount
and other specifically investigated proteins were not up-
regulated after irradiation at the time point of CM-
harvesting. Furthermore, LDH, a classic marker for cell
leakage, was not increased in response to IR. Regardless of
its mechanism, it will be important to investigate the func-
tional effect of IR-enhanced LOX levels in the blood on
tumor cell dissemination and premetastatic niches [27].
Detailed analysis of dose- and time dependence will be
part of upcoming experiments investigating the relevance
of IR-induced LOX secretion in vivo. In a tumor-
unrelated in vivo model of pulmonary fibrosis, we recently
observed that LOX expression is increased in fibrotic
lungs induced by both irradiation and bleomycin [41].
Irradiation of lung tissue created LOX-dependent collagen
crosslinking and subsequent lung fibrosis with a growth-
permissive fibrotic microenvironment supporting meta-
static growth. Our new results now demonstrate that IR
also induces LOX secretion from tumor cells and in the
tumor which is part of an early response and might not
affect distant fibrogenesis, but might induce a bystander
effect, as suggested by our in vitro data, on sublethally-
irradiated or even distant unirradiated tumor cells. Of
note, we here did not observe an increase of murine LOX
in the serum of mice not carrying tumor xenografts but
still locoregionally irradiated (data not shown). Further-
more, based on the detection of LOX in the serum of mice
bearing irradiated tumor xenografts, future studies should
also investigate LOX levels in human patients undergoing
radiotherapy treatment.
Previous studies identified increased expression and
secretion of LOX from tumor cells exposed to physio-
logical levels of hypoxia as well as association of LOX
with metastasis and poor survival in mammary carcin-
oma and head and neck cancer patients. Furthermore,
inhibition of LOX activity eliminated tumor dissemin-
ation in an orthotopic mammary tumor model. There-
fore, anticancer agents that concomitantly downregulate
LOX might thereby also reduce tumor dissemination
of sublethally treated tumor cells [27,28,30]. As such,
epothilones including the clinically relevant compound
patupilone, might be interesting candidates. While our
study did not find a role for the microtubule stabilizing
agent patupilone in inhibiting IR-induced LOX, patu-
pilone did reduce hypoxia-induced LOX secretion. Of
interest, we previously demonstrated that patupilone is
as potent under normoxic as under hypoxic conditions
and strongly sensitizes for ionizing radiation in particular
in vivo. This coincides with interference of patupilone
with the HIF-transcriptome, previously demonstrated for
hypoxia-induced VEGF secretion [38]. Thus, the anti-
metastatic effect of patupilone and related epothilone-
derivatives, as characterized in other studies, might in part
be due to reduced LOX secretion under hypoxia in
patupilone-treated xenografts [42,43].
Conclusion
Our results demonstrate to our best knowledge for the first
time that LOX is secreted from tumor cells also in response
to irradiation and indicate a differential regulation of LOX-
expression and secretion in response to IR and hypoxia.
These results suggest that LOX may contribute towards an
IR-induced migratory phenotype in sublethally-irradiated
tumor cells and tumor progression.
Additional files
Additional file 1: Figure S1. No unspecific leakage of proteins in
response to irradiation. Human angiogenesis antibody array showing
secretion of multiple factors in supernatants derived from naïve
(sham-irradiated) and irradiated (5 Gy) human A549 cells. Conditioned
media was harvested 24 hours after irradiation. (B) Bar graph showing
the levels of PDGFA (platelet-derived growth factor alpha) and THBS1
(Thrombospondin 1) in conditioned media derived from sham-irradiated
or irradiated A549 cells. Levels of secreted proteins were measured by
ELISA. (C) LDH-release in response to increasing doses of irradiation in
the supernatants of A549-treated cells 24 hours after irradiation.
Additional file 2: Figure S2. LOX secretion in response to tumor cell
irradiation in different tumor cell lines. ELISA-based quantification of LOX
in supernatants from A549 (A) SW620 (B) and A431 (C) tumor cells. CMs
(from unirradiated and irradiated cells) were collected at the indicated
time points after irradiation (10 Gy). The ratio of LOX in the CMs derived
from irradiated versus unirradiated cells are shown. (*: significantly
different from control conditions (0 Gy, 0 hour time point)).
Additional file 3: Figure S3. Hypoxia but not IR enhances LOX gene
transcription in SW620 colon carcinoma cells. LOX gene transcription was
determined by RT-PCR, 16 h after treatment with increasing doses of IR
and hypoxia, averaged over 3 independent experiments.
Additional file 4: Figure S4. Absence of IR-induced LOX gene
transcription. LOX gene transcription was determined in A549 lung
carcinoma and SW620 colon carcinoma at the indicated timepoints after
irradiation with 10 Gy. IR-induced CDKN1A gene expression was used as
positive control. LOX and CDKN1A gene expression were determined by
RT-PCR and averaged over 3 independent experiments.
Additional file 5: Figure S5. IR-enhanced LOX in tumor xenografts.
Tumor tissue from A549-derived tumor xenografts treated with 1 × 10 Gy
and 2 × 10 Gy (with 12 h between fractions) were evaluated by
immunohistochemistry for LOX at different time points after irradiation.
Whole tumor sections were quantified for specific LOX-staining intensity.
Each treatment group consists of 3 animals and at least 3 sections per
tumor were analyzed. Bars for each treatment group show mean of %
of area with no, low, medium and intense staining.
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